Inmaculada Baeza

Inmaculada Baeza

Auto-generated profile, based on publicly available information

Inmaculada Baeza

Child and Adolescent Psychiatry and Psychology Department, Hospital Clínic de Barcelona, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2022 in Child Abuse & Neglect
Verified
Journal Article
Closed access
ADAndrea Daniel-Calveras
Andrea Daniel-Calveras
NBNuria Baldaquí
Nuria Baldaquí
IBInmaculada Baeza
Inmaculada Baeza

1 June 2021 in Schizophrenia Research
Verified
Journal Article
Open access
AFAdriana Fortea
Adriana Fortea
ABAlbert Batalla
Albert Batalla
Joaquim RaduàJoaquim Raduà
Joaquim Raduà
PEPhilip Van Eijndhoven
Philip Van Eijndhoven
IBInmaculada Baeza
Inmaculada Baeza
GSGisela Sugranyes
Gisela Sugranyes
Gray matter and cortical thickness reductions have been documented in individuals at clinical high-risk for psychosis and may be more pronounced in those who transition to psychosis. However, these findings rely on small samples and are inconsistent across studies. In this review and meta-analysis we aimed to investigate neuroanatomical correlates of clinical high-risk for psychosis and potential predictors of transition, using a novel meta-analytic method (Seed-based d Mapping with Permutation of Subject Images) and cortical mask, combining data from surface-based and voxel-based morphometry studies. Individuals at clinical high-risk for psychosis who later transitioned to psychosis were compared to those who did not and to controls, and included three statistical maps. Overall, individuals at clinical high-risk for psychosis did not differ from controls, however, within the clinical high-risk for psychosis group, transition to psychosis was associated with less cortical gray matter in the right temporal lobe (Hedges' g = -0.377), anterior cingulate and paracingulate (Hedges' g = -0.391). These findings have the potential to help refine prognostic and etiopathological research in early psychosis.

14 September 2021 in The Journal of Clinical Psychiatry
Verified
Journal Article
Closed access
IBInmaculada Baeza
Inmaculada Baeza
ESElena de la Serna
Elena de la Serna
SASilvia Amoretti
Silvia Amoretti
MCManuel J. Cuesta
Manuel J. Cuesta
CDCovadonga M. Díaz-Caneja
Covadonga M. Díaz-Caneja
PGPEPs Group
PEPs Group
Most research on first-episode psychosis has focused on adults. This study aimed to explore differences in early-life characteristics of patients with early-onset versus those with adult-onset psychotic disorders and identify predictors of earlier onset.

15 January 2022 in Nutritional Neuroscience
Verified
Journal Article
Closed access
NPNuria Prades
Nuria Prades
EVEva Varela
Eva Varela
IFItziar Flamarique Flamarique
Itziar Flamarique Flamarique
RDRamon Deulofeu
Ramon Deulofeu
IBInmaculada Baeza
Inmaculada Baeza
Nutrition is fundamental for brain development, but relatively little is known about water-soluble vitamin (WSV) levels and the effect of supplementation on psychiatry symptoms in children and adolescents (CAD) with psychiatric disorders. Our team systematically reviewed all studies concerning WSV abnormalities or supplementation in CAD with any psychiatric disorder. We searched for original studies published between 1990 and 15/05/2020 which were not based on retrospective chart review and which included WSV blood level measurements or investigated the effect of WSV supplementation on psychiatric symptoms in psychiatric patients aged 18 or under. Forty-two articles were included, 69% of which (N = 29) examined Autism Spectrum Disorders (ASD), with most of these assessing folate or vitamin B12 supplementation (N = 22, 75.9% of ASD studies). Meta-analyses showed significantly lower vitamin B12 levels in ASD and ADHD patients vs. healthy controls (HC), while folate levels were higher in ADHD patients vs. HC. Most of the studies (9/10, 90%) showed a decrease in symptoms as measured by clinical scales after supplementation. There was significant heterogeneity between the studies, however many found different types of vitamin abnormalities in CAD with psychiatric disorders.

28 December 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ESEstela Salagre
Estela Salagre
IGIria Grande
Iria Grande
BSBrisa Solé
Brisa Solé
GMGisela Mezquida Mateos
Gisela Mezquida Mateos
MCManuel J. Cuesta
Manuel J. Cuesta
PGPEPs Group
PEPs Group
Being able to predict functional outcomes after First-Episode Psychosis (FEP) is a major goal in psychiatry. Thus, we aimed to identify trajectories of psychosocial functioning in a FEP cohort followed-up for 2 years in order to find premorbid/baseline predictors for each trajectory. Additionally, we explored diagnosis distribution within the different trajectories. A total of 261 adults with FEP were included. Latent class growth analysis identified four distinct trajectories: Mild impairment-Improving trajectory (Mi-I) (38.31% of the sample), Moderate impairment-Stable trajectory (Mo-S) (18.39%), Severe impairment-Improving trajectory (Se-I) (12.26%), and Severe impairment-Stable trajectory (Se-S) (31.03%). Participants in the Mi-I trajectory were more likely to have higher parental socioeconomic status, less severe baseline depressive and negative symptoms, and better premorbid adjustment than individuals in the Se-S trajectory. Participants in the Se-I trajectory were more likely to have better baseline verbal learning and memory and better premorbid adjustment than those in the Se-S trajectory. Lower baseline positive symptoms predicted a Mo-S trajectory vs. Se-S trajectory. Diagnoses of Bipolar disorder and Other psychoses were more prevalent among individuals falling into Mi-I trajectory. Our findings suggest four distinct trajectories of psychosocial functioning after FEP. We also identified social, clinical, and cognitive factors associated with more resilient trajectories, thus providing insights for early interventions targeting psychosocial functioning.

20 January 2023 in Pediatric Drugs
Verified
Journal Article
Open access
PDF file
IBInmaculada Baeza
Inmaculada Baeza
AFAdriana Fortea
Adriana Fortea
DIDaniel Ilzarbe
Daniel Ilzarbe
GSGisela Sugranyes
Gisela Sugranyes
Background Long-acting injectable antipsychotics (LAIAs) are an efficacious and well-tolerated treatment in adults with schizophrenia spectrum disorders (SSD). However, there is less evidence for their use in children and adolescents. Objectives The aim of this systematic review was to summarize findings regarding the effectiveness and side effects of LAIA in children and adolescents with SSD. Methods Four databases (Web of Science, PubMed, MEDES, and Dialnet) were systematically searched for articles published between inception and 12 March, 2022, with the following inclusion criteria: (1) original articles or case reports; (2) providing data on efficacy/effectiveness or safety/tolerability of LAIA treatment in children and adolescents diagnosed with SSD (schizophrenia, schizoaffective disorder, schizophreniform disorder, non-affective psychotic disorder); (3) mean age of samples ≤ 18 years; and (4) written in English or Spanish. Exclusion criteria were review articles, clinical guides, expert consensus as well as posters or oral communication in conferences. The risk of bias was assessed using the ROBIS tool. Results From 847 articles found, 13 met the inclusion criteria. These included seven single case reports or case series, four retrospective chart reviews, a 24-week open-label trial, and one observational prospective study, covering a total of 119 adolescents (aged 12–17 years) with SSD. Almost all the articles described data on second-generation LAIA (53 patients on risperidone [once every other week], 33 on paliperidone palmitate [once monthly], 10 on aripiprazole [once monthly], and two on olanzapine pamoate [once monthly]). Twenty-one patients were reported to be only on first-generation LAIAs. Non-adherence was the main reason for starting an LAIA. In all of the studies, the use of LAIAs was associated with improvement in the patients’ symptoms. Conclusions There are few studies assessing the use of LAIAs in adolescents with SSD. Overall, these treatments have suggested good effectiveness and acceptable safety and tolerability. However, we found no studies examining their use in children aged < 12 years. The problems and benefits linked to this type of antipsychotic formulation in the child and adolescent population require further study, ideally with prospective, controlled designs.